Sullivan Christopher Ryan 4
4 · Avalo Therapeutics, Inc. · Filed Apr 1, 2025
Insider Transaction Report
Form 4
Sullivan Christopher Ryan
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2025-03-28+24,200→ 24,206 total - Tax Payment
Common Stock
2025-03-28$8.46/sh−7,285$61,631→ 16,921 total - Exercise/Conversion
Restricted Stock Units
2025-03-28−24,200→ 48,400 total→ Common Stock (24,200 underlying)
Footnotes (2)
- [F1]Restricted stock units convert into common stock on a one-for-one basis.
- [F2]On August 13, 2024, the Reporting Person was granted 72,600 restricted stock units, vesting 1/3 on March 28, 2025, March 28, 2026, and March 28, 2027, subject to the Reporting Person's continued service on such vesting date.